Oculus Innovative Sciences Introduces Microcyn(R) Solution for Use in Post-Surgical Wounds to U.S. Hospitals and Physicians

PETALUMA, Calif.--(BUSINESS WIRE)-- Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), a commercial medical technology company that designs, produces and markets safe and effective tissue care products based upon the Microcyn(R) Technology platform, today unveiled Microcyn Solution with preservatives, at the New York Podiatric Clinical Conference & Exhibition being held in downtown Manhattan, January 29-31.

The Microcyn(R) Solution for professional use is intended for the irrigation and management via debridement of post-surgical wounds. Available in 500 mL and 990 mL units with attached pharmasling(R) hangers, Microcyn Solution has no known drug/treatment interactions or contraindications; is non-foaming and safe to use around nose, mouth and eyes; does not contain antibiotics and will not facilitate bacterial resistance. With a laboratory-proven inactivation of bacteria, fungus and spores in-solution, Microcyn delivers a six-log reduction of MRSA, VRE, Pseudomonas, Acinetobacter and many other pathogens in just 30 seconds as labeled and cleared by the FDA. The patented Microcyn Solution can be easily and harmlessly disposed of without the added cost of special handling. The Microcyn Technology has treated over two million patients worldwide and has been used in 30 clinical studies, all without a report of a single serious adverse effect.

For more information, pricing or ordering visit http://store.oculusis.com/ or phone 1-800-931-3205.

Adam Landsman, DPM, Ph.D. and assistant professor of surgery at Harvard Medical School in Boston, who was lead investigator in a Phase II trial in which the Microcyn Technology was used to treat mildly infected diabetic foot ulcers in 2007, stated: "The current standard for surgical wound cleansing and irrigation involves the use of products that do not kill the MRSA infection in-vitro. This is important in light of the skyrocketing proliferation of these dangerous bacteria as well as the evolving 'super bug' mutations. Microcyn is also highly attractive since it does not produce foam, which hampers visualization of the wound. And finally, with the health community so vitally focused on cost savings, the Microcyn Solution will actually cost less than the current combination of saline and expensive antibiotics."

Oculus is initially introducing the Microcyn Solution with a 14-person sales force, which will be expanded as the company addresses this growing healthcare challenge. According to Medtech Insight, Inc, there were 39 million acute surgeries and nine million trauma wounds in the United States alone in 2004.

About Oculus Innovative Sciences

Oculus Innovative Sciences is a commercial medical technology company that designs, produces and markets safe and effective tissue care products based upon the Microcyn(R) Technology platform, which significantly reduces the need for antibiotics while reducing infections and accelerating healing. The Microcyn Technology addresses the need for improved solutions in multiple markets including dermatology, oral care, cosmeceutical, wound care and others. It features a biocompatible, shelf-stable solution that is currently commercialized in the United States, Europe, India, China and Mexico and select Middle East countries under various country specific regulatory clearances and approvals. Several solutions derived from this platform have demonstrated, in a variety of research and investigational studies, the ability to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria (including MRSA and VRE), viruses, fungi and spores, increase blood flow to the wound site, and reduce both inflammation and pain while assisting in faster wound closure. The company's headquarters are in Petaluma, California, with operations in Latin America. More information can be found at www.oculusis.com.

Forward-Looking Statements

Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the Company's commercial and technology progress and future financial performance. These forward-looking statements are identified by the use of words such as "intended," "introducing," "expanded" and "addresses," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the Company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the Company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company's products will not be as large as expected, the Company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical studies, the Company may not meet its future capital needs, and its ability to obtain additional funding, as well as uncertainties relative to varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission including the annual report on Form 10-K for the year ended March 31, 2009. Oculus Innovative Sciences disclaims any obligation to update these forward-looking statements except as required by law.

Oculus, Microcyn Solution, Microdacyn60, Dermacyn and Microcyn Technology are trademarks or registered trademarks of Oculus Innovative Sciences, Inc. All other trademarks and service marks are the property of their respective owners.

Editor Note: High-resolution product photos available upon request.

    Source: Oculus Innovative Sciences, Inc.

Released January 28, 2010